Prostate Cell News Volume 10.14 | Apr 26 2019

TOP STORY

Engineering Osteoblastic Metastases to Delineate the Adaptive Response of Androgen-Deprived Prostate Cancer in the Bone Metastatic Microenvironment

Direct co-culture of androgen receptor-dependent/independent cell lines led cancer cells to display functional and molecular features as observed in vivo. Co-cultured cancer cells showed increased affinity to the microtissues, as a function of their bone metastatic potential. [Bone Res] Full Article

(Ranked by impact factor of the journal)

Cholesterol Induces Epithelial-to-Mesenchymal Transition of Prostate Cancer Cells by Suppressing Degradation of EGFR through APMAP

Researchers found that cholesterol induced the epithelial-to-mesenchymal transition through extracellular regulated protein kinases 1/2 pathway activation, which was mediated by epidermal growth factor receptor (EGFR) and adipocyte plasma membrane-associated protein (APMAP) accumulation in cholesterol-induced lipid rafts. [Cancer Res] Abstract

A Novel RNA Aptamer Identifies Plasma Membrane ATP Synthase Beta Subunit as an Early Marker and Therapeutic Target in Aggressive Cancer

Apt63 bound to plasma membranes of multiple aggressive breast and prostate cell lines, but not to normal breast and prostate epithelial cells, and weakly or not at all to non-metastasizing cancer cells; binding led to rapid cell death. [Breast Cancer Res Treat] Full Article

Altered Expression and Localization of Tumor Suppressive E3 Ubiquitin Ligase SMURF2 in Human Prostate and Breast Cancer

Scientists found that while in normal cells and tissues SMURF2 had a predominantly nuclear localization, in prostate and aggressive breast carcinomas SMURF2 showed a significantly increased cytoplasmic sequestration, associated with disease progression. [Cancers] Full Article

RSPO3 Is a Prognostic Biomarker and Mediator of Invasiveness in Prostate Cancer

For elucidation of the biological effect of R-Spondin 3 (RSPO3), the authors used siRNA technology to reduce the levels of RSPO3 in established prostate cancer cell lines, and performed in vitro proliferation, invasion, western blotting for EMT markers and clonogenic survival assays for radiation resistance. [J Transl Med] Full Article

Midkine Silencing Enhances the Anti-Prostate Cancer Stem Cell Activity of the Flavone Apigenin: Cooperation on Signaling Pathways Regulated by ERK, p38, PTEN, PARP, and NF-κB

Investigators explored the possible therapeutic use of midkine silencing, apigenin treatment, and a combination of both on human prostate cancer and prostate cancer stem cells (CSCs). CD44⁺CD133⁺ PC3 and CD44⁺ LNCaP CSCs were isolated from their parent cell lines. [Invest New Drugs] Abstract

Upregulation of MicroRNA-21 Promotes Tumorigenesis of Prostate Cancer Cells by Targeting KLF5

Scientists found that miR-21 was an unfavorable factor and correlated positively with tumor grade in prostate cancer (PCa) patients from the TCGA database. MiR-21 was more highly expressed in androgen-independent PCa cells than in androgen-dependent PCa cells. [Cancer Biol Ther] Abstract

Reduced FRG1 Expression Promotes Prostate Cancer Progression and Affects Prostate Cancer Cell Migration and Invasion

Immunohistochemistry was performed to determine FRG1 expression in patient samples. FRG1 expression perturbation was done to investigate the effect of FRG1 on cell proliferation, migration and invasion, in DU145, PC3 and LNCaP cells. [BMC Cancer] Full Article

Bufalin Suppresses the Migration and Invasion of Prostate Cancer Cells through HOTAIR, the Sponge of miR-520b

Researchers investigated the possible network related to the antimetastatic effect of bufalin in prostate cancer cells. They demonstrated that bufalin dose-dependently suppressed the proliferation of prostate cancer DU145 and PC3 cells with IC₅₀ values of 0.89 and 1.28 µM, respectively. [Acta Pharmacol Sin] Abstract

Pomolic Acid Exhibits Anticancer Potential against a Docetaxel-Resistant PC3 Prostate Cell Line

The authors demonstrated that PC3R cells present multidrug resistance and EMT phenotype and expressed active P-gp/ABCB1 and MRP1/ABCC1. [Oncol Rep] Abstract

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

Galectins in Prostate and Bladder Cancer: Tumorigenic Roles and Clinical Opportunities

Understanding the roles of galectin family proteins in the development and progression of prostate and bladder cancer could yield key insights to inform the clinical management of these diseases. [Nat Rev Urol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Mateon Enters into Merger Agreement with Oncotelic

Mateon Therapeutics, Inc. and Oncotelic Inc. announced that they have entered into a definitive agreement with respect to a merger, creating a publicly traded immuno-oncology company with a robust pipeline of first in class TGF-β immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. [Mateon Therapeutics, Inc.] Press Release

Nymox Reports Pre-NDA CMC Meeting with the FDA

Nymox Pharmaceutical Corporation announced that it has held its pre-New Drug Application (NDA) Chemistry Manufacturing and Controls (CMC) meeting with the FDA regarding its lead product candidate Fexapotide Triflutate, a novel prostate injectable developed for the treatment of enlarged prostate. [Nymox Pharmaceutical Corporation] Download Press Release

US Universities Reassess Collaborations with Foreign Scientists in Wake of NIH Letters

Kuspa’s attempt to stay ahead of NIH came to naught. A few months into the audit, Baylor College of Medicine received letters from the US National Institutes of Health (NIH) asking about four scientists it believed had violated the agency’s rule requiring them to disclose all foreign ties relating to their research. [ScienceInsider] Editorial

Elsevier and Norway Agree on New Open-Access Deal

After unsuccessful negotiations between a coalition of Norwegian organizations and the academic publisher Elsevier culminated in cancelled subscriptions earlier this year, the two have successfully established a new nationwide licensing agreement. [The Scientist] Editorial

Fearing No-Deal Brexit, European Funder Orders UK Researchers to Transfer Grants

The prospect of Brexit, the United Kingdom’s departure from the European Union, has loomed long and large over researchers, but the effects on funding, so far, have been speculative. Now, a European funding agency has made a pre-emptive strike in advance of Brexit, changing a policy that directly impacts grants in the United Kingdom. [ScienceInsider] Editorial

NEW Advanced Prostate Cancer Consensus Conference (APCCC) 2019
August 29-31, 2019
Basel, Switzerland

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Research Position – Molecular Biology & Cancer Research (Augusta University)

NEW Postdoctoral Research Fellow – Mechanisms of Prostate Cancer Resistance (Fred Hutchinson Cancer Research Center)

NEW Postdoctoral Fellow – Prostate Cancer Biology (University of Maryland)

Postdoctoral Fellow – Cancer Systems Imaging (The University of Texas MD Anderson Cancer Center)

Research Assistant – Prostate Cancer Biology (University of Oxford)

Postdoctoral Fellow and PhD Student Position – Hormone Driven Cancer (Institute of Oncology Research)

Postdoctoral Position – Prostate Cancer (UT Health San Antonio)

Postdoctoral Position – Microenvironment & Cancer (Brigham and Women’s Hospital)

Postdoctoral Fellow – Prostate Cancer & Stem Cell Biology (City of Hope)

Postdoctoral Fellow – Cancer Immunotherapy (University of Notre Dame)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.